Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion type Assertion NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_head.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion description "[The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_provenance.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion evidence source_evidence_literature NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_provenance.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion SIO_000772 18397680 NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_provenance.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion wasDerivedFrom befree-20150227 NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_provenance.
- NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_assertion wasGeneratedBy ECO_0000203 NP711948.RAxEg8cjIZ8rKYIACH2J7nmNikMrpHzJ4NtPwmq73wPjM130_provenance.